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NADH & Jet Lag 
Abstract 
Background: Current remedies fo r jet lag (phototherapy, melatonin , stimulant, and 
sedative medications) are limited in efficacy and practicality. The efficacy of a 
stabi lized, sublingual form of reduced nicotinamide adenine dinucleotide (NADH, 
E NADAlert®, Menuco Corp.) as a countermeasure for jet lag was examined. 
Hypothesis: Because NADH increases cellular production of ATP and fac ilitates 
dopami ne synthesis, it may counteract the effects of jet lag on cogn iti ve fu nction ing and 
sleepiness. Methods: Thirty-five health y, empl oyed subjects part icipated in this double-
blind, placebo-controlled study. Training and baseline testing were conducted on the 
West Coast before subjects flew overnight to the East Coast, where they would 
experi ence a 3-hour time di fference. Upon aITival, individua ls were rando ml y ass igned 
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to receive either 20 mg of sublingual stabi li zed ADH (n=1 8) or identical placebo tablets 
(n=17). All participants completed computer-administered tests (including CogScreen7) 
to assess changes in cognitive functioning, mood , and sleepi ness in the morning and 
afternoon . Results: Jet lag resulted in increased sleepiness for over half the participants 
and deterioration of cognitive functioning for approxi mately one third. The morning 
fo llowing the fli ght, subjects experienced lapses of attention in addition to di sruptions in 
worki ng memory, divided attention, and visual perceptual speed. Indi viduals who 
received NADH performed significantly better on 5 of 8 cognitive and psychomotor test 
measures (P< .OS) and showed a trend for better performance on the other three measures 
(P~.lO) . Subjects also reported less sleepiness compared with those who received 
placebo. No adverse effects were observed with NADH treatment. Conclusions: 
Stabilized NADH signi ficantly reduced jet lag-induced disruptions of cogn itive 
functioning, was easily admini stered, and was fou nd to have no adverse side effects. _ 
Keywords: jet lag, cognitive testing, fatigue countermeasures, NADH 
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Jet lag is a constellation of symptoms that occur after flying across time zones. It 
affects a large number of travelers and aircrew (1). These symptoms include: general 
malaise and fatigue, disrupted sleep, gastrointestinal distress, and memory loss (2-7). 
Rosekind (8) estimates that jet lag can degrade decision-making abilities, communication, 
and memory by 30% to 70%. The disruption of the body's entrainment of internal 24-
hour cyc les of temperature, sleep initiation and other activities to the day-light cycle is 
believed to be the tIigger for jet lag (9, 10) . Today's modem jet traveler (soldier, 
busi nessperson , athlete, or tourist) often is required to perform at a high functional level 
upon reaching their destination . Furthermore, the problems of jet lag have been 
compounded in recent years because business travelers are taking more international trips 
and staying fewer days at their destination . 
Research on the mitigation of jet lag has emphasized methods to speed the 
entrainment of the circadian rhythm to the new time zone (l1). These methods include 
sleep scheduling, phototherapy, and administration of sedative and/or stimulant 
medications (12-14). Each of these methods has been found to have some merit, though 
each has potential adverse side effects and some are considered impractical (15). 
An alternative approach to countering the effects of jet lag is to provide the 
traveler with the additional energy and alertness needed to mitigate jet lag symptoms 
while readjusting to a new time zone. One potential method for providing energy is the 
energy producing coenzyme NADH (B-nicotinamide adenine dinucleotide, reduced form 
Coenzyme 1). We investigated the effects of stabilized, sublingual NADH on the 
cogniti ve functioning of healthy indi vi duals on the day following an overnight flight 
across NOtth America. The sublingual form of NADH (ENADAlert™, Menuco 
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Corporation) was chosen to maximize the absorption and optimize bioavailability of the 
coenzyme. Previously, NADH has been shown to facilitate production of dopamine and 
norepinephrine (16). Furthermore, NADH has been demonstrated to increase cellular 
energy production of ATP (17), to aid in the repair of damaged DNA (18), and to 
function as a potent antioxidant (19). All of these properties of NADH led us to 
investigate the compound as a potential countermeasure for jet lag. Furthermore, c linica l 
studies have demonstrated that oral NADH is effecti ve in reducing symptoms of chronic 
fatigue syndrome, Parkinson's disease, Alzheimer's disease, and depression (20-23). In 
these studies , long-term (4-week to 6-month) oral use of stabilized ADH was associated 
with clinical improvement in energy level and cognitive functioning without adverse 
effects. 
We hypothesized that administration of sub lingua l NADH to travelers would 
spec ifica lly result in a reduction of the impact jet lag has on cognitive function ing and 
sleepiness, enabling travelers to return to their normal levels of physical and mental 
activity upon arriving in a new time zone. 
METHODS 
Subjects 
Subjects (n=36) were volunteers between 35 and 55 years of age, in good general 
physical health. All subjects were verbally informed of the intent and procedures of the 
study during a pre-screening telephone interview. Written informed consent was 
obtained prior to the history and physicaL At the screening visit, subjects were urine 
tested to screen for the use of illicit drugs and pregnancy. Cognitive screening with the 
Trail Making Test and Symbol Digit Modalities Test (24) was used to exclude subjects 
4 
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with cognitive function test scores> 1 SD below the mean for their age. Subjects were 
required to be gainfully employed, to have completed 14 years of formal education, and 
to have none of the following conditions; history of substance abuse, obesity (body mass 
index > 30 kglm 2), air sickness , pregnancy, nicotine use (within 6-months), mental health 
di sorder (within 1 year), or sleep disorder. In addition, subjects were required to have a 
normal day/ni ght sleep schedule in their home time zone, and to have an Epworth 
Sleepiness Scale rating> 8 at baseline (25). Subjects were not permitted to be taking 
antidepressant medications, eNS stimulants, neuroleptics, Ginseng, Gingko Biloba, 
mel atonin , phosphatylcholine, n-acetyl carnatene, or other medi cations/nutritional 
supplements reported to enhance cognitive functioning within 90 days of the study. 
DUling the study, subjects were not permitted to use caffeine, alcohol or to take any 
prescliption or over-the-counter medications known to enhance or depress CNS 
functioning. The study protocol and consent fo rm were reviewed and approved for 
human subjects by the Biomedical Research Institute of America (San Diego, California). 
Procedure 
Subjects arrived at the San Diego, California test site at 1200 hours on the day of 
the flight. The study protocol was reviewed with the subjects and they were then each 
issued a laptop computer (IBM Thinkpad Model 760) and familialized with the tests and 
measures to be used in the study. At approximately 1500 hours subjects were 
administered the entire battery of tests to establish their baseline performance (Baseline). 
Subjects also received training in the method for taking the sublingual tablets. Subjects 
were transported to the San Diego Airport and flown to Phoenix, Arizona where they 
were shuttled to a conference room at a nearby hotel, provided dinner, and readministered 
the battery -of tests at approximately 2030 hours . Subjects were shuttled back to the 
airport and boarded a fl ight to Baltimore, Maryland at 2230 hours. Thirty minutes into 
the flight the subjects were instructed to complete a subset of the battery of tests. 
5 
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Subjects were pennitted to sleep after completing the tests. The duration of the fli ght 
from Phoenix to Baltimore is approximately 4 hours. Furthennore, there is a 3-hour time 
difference between San Diego and Baltimore. The local time in Baltimore upon ani val 
was approximately 0600 hours . After breakfast, subjects were shuttled to the 
Washington , DC test site where they anived at approximately 0800 hours. 
Sublingual NADH 20 mg (4 tablets of sublingual ENADAlert® 5 mg) or an equal 
number of identical placebo tablets were administered by study site personnel to the 
subjects upon their ani val at the Washington test site. At the test site, subjects' activities 
were carefully monitored to avoid dehydration , exposure to daylight (subjects were kept 
indoors) and hunger (they were provided breakfast and lunch, which all subjects ate.) 
Caffeine intake was stlictly prohibited. Study drug was provided in moisture-proof, 
airtight, labe led medication bottles labeled with the subject's identification number. 
Subjects completed the battery of tests 90 minutes after dosing, at approximately 
0930 hours (AM test) . Testing was repeated at 1230 hours (PM test). Subjects were 
dismissed from the study at 1400 hours . 
Measurements 
Cognitive Tests 
Kay Continuous Performance Test (KCPT) (26) 
This test provides a measure of sustained attention and vigilance. On this 
computer-administered cognitive test, subjects watch a computer monitor and respond 
only when seeing a target symbol that occurs at low frequency (i.e., 5%). The number of 
errors of omission (i.e., lapses of attention) and en'ors of commission were used to 
calculate total errors. 
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CogScreen 
The following four CogScreen subtests were administered: 
Shifting Attention Test: Instruction Condition: Measure of working memory. 
Subject reads a two-word instruction and then applies the instruction to the screen 
that follows . The accuracy, throughput (number of correct responses per minute), 
and median response time for correct responses were recorded. 
Matching to Sample Test: Measure of visual perceptual processing speed and 
working memory: Subject views a 4x4 checkerboard pattern and then on the 
creen that follows, the subject selects the matching checkerboard pattern. The 
accuracy of responses, the throughput (number of correct responses per minute) 
and the median response time for correct responses were recorded. 
Visual Sequence Comparison: Measure of visual processing of number/letter 
sequences: The accuracy of responses, the throughput (number of correct 
responses per minute) and the median response time for correct responses 
(VSCRTC) were recorded. 
Dual Task Test: Tracking Alone: Measure of psychomotor functioning. 
Subject's task is to maintain the central position of an unstable cursor that moves 
along a horizontal line using the left and right cursor keys. The average absolute 
tracking error and the number of tracking failures were recorded. 
Mark Numbers Test: Complex Cognitive Assessment Battery (CCAB) (27) 
Computer-administered test measuring working memory and divided attention: 
The subject identifies and "marks" numbers in a spreadsheet according to an instruction 
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(e.g. Mark all even numbers between 20 and 46). While performing this task, the subject · 
is interrupted and instructed to locate and mark the smaller or larger of two flashing 
numbers . After performing the secondary task the subject resumes the primary task. The 
total score (a derived measure of the total number of correct marks , the speed of 
completing the task, and performance on the secondary task, and the mean reaction time 
to responding to the secondary task were recorded. 
Automated Neuropsychological Assessment Metrics (ANAM) (26) 
Two sub-tests were selected from the ANAM battery of tests: 
Running Memory Test: Measure of vigilance and working memory: Subject is 
instructed to indicate whether or not the letter being shown on the screen is the 
same as the previous letter. The accuracy of responses, the throughput (number of 
correct responses per minute) and the mean response time for correct responses 
were recorded. 
Math Test: Measure of working memory and math reasoning: Subject is presented 
with 3 numbers and two operation signs (e.g., 3 + 5 - 2) and is instructed to decide 
whether the total is greater than 5 or less than 5. The accuracy of responses , the 
throughput (number of correct responses per minute) and the mean response time 
for correct responses were recorded. 
Self-Report Mood Measures 
Walter Reed Mood Scale (26) 
Subjects indicate their agreement or qisagreement with an adjective that is 
presented as a description of their current mood. Scales include measures of fatigue and 
activity. 
8 
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Stanford Sleepiness Scale (25) 
This is a 7-point self-repol1 scale of CUITent sleepiness, with 1 being least sleepy 
and 7 being most sleepy. 
Statistical Analyses 
9 
For continuous measures , the effects of sublingual NADH were assessed by 
repeated measures analysis of valiance (SPSS-PC, Version 10.7). Tests with categolical 
results (KCPT errors of omission and commission, Dual Task Test Hits, Stanford 
Sleepiness Scale) were analyzed by Chi-square test. These methods were used to provide 
a comparison of the NADH and placebo groups at Baseline in San Diego, CA, the 
morning in Washington. D.C. (AM), and the afternoon in Washington, D .C. (PM). 
Significant group by session interaction effects are repol1ed. Statistical significance was 
set at P < .05. 
RESULTS 
Subject Demographics: Thirty-six subjects enrolled in the study (19 males and 
17 females) between 35 and 55years of age. One male subject who had completed 
screening failed to appear for the test session. Subjects were randomly assigned to the 
placebo and NADH groups. The groups did not differ in age (NADH age = 43.9 +1- 6.9; 
Placebo 42.8 +1- 6.1) or gender composition (NADR9 males/9 females; Placebo 9 
males/8 females). 
Adverse Events: Fourteen subjects reported having headaches during the study. 
The onset of the headache occurred before the administration of NADH or placebo for 
ten of these subjects . Two subjects in each group had headaches that began after the 
administration of either NADH or placebo. Subjects were given acetaminophen or 
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ibuprofen for the headaches. For eight subjects the headache resolved prior to the 
ad mini stration of NADH or placebo. 
Vigilance: The ANAM Running Memory Test and the KCPT were the primary 
measures of vigilance. Useable data for the AN AM Running Memory Test was obtained 
for onl y 28 subjects . Five of the subjects were not using the COITect key to respond and 
two subjects had response times (at all 3 sessions) that were extreme outliers. For the 
remaining 14 NADH and 14 placebo subjects , there was a baseline difference in reaction 
time (P ==.005 ). However, the groups did not di ffer at baseline with respect to number of 
items completed or accuracy. The Group x Sess ion interaction is significant for acc uracy 
(P =.036). Accuracy for placebo subjects dropped from 95 % at baseline to 91 % at the 
AM and PM testing. For NADH subjects Running Memory accuracy scores remained 
stable across all three sessions at approximatel y 96% [Figure 1 Here]. 
On the KCPT test, there were no group differences at baseline. Only data for the 
30 subj ects with a normal baseline performance (i.e., 0 to 1 omission error) were 
analyzed. Twelve of the 30 subjects (36% NADH, 44% Placebo) made two or more 
errors in the AM. By the PM, subjects receiving NADH made significantly fewer total 
errors (compared to baseline) than subjects receiving placebo (p<.05). Eighty six 
percent of NADH subjects had resumed a normal level of perfonnance compared to 63% 
of placebo subj ects (P <.08). 
Working Memory: There were no baseline group differences on the Shifting Attention Test-
Instruction Condition. The Group x Session effect was significant (P<.05). Analysis of contrasts shows 
that subjects in the NADH group correctly completed 13.2 more problems per minute at AM vs. baseline 
compared to 6.8 more problems correctly completed per minute for the placebo group . For the placebo 
subjects, accuracy dropped from 93% at baseline to 91 % at the AM test. For NADH subjects performance 
improved from 92.5% at baseline to 95% at the AM test session [Figure 2 Here]. 
On the ANAM Math Test the Group x Session effect approached signi ficance for 
the measure of throughput (P <.07). For subjects in the NADH group there was a 15% 
10 
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improvement relati ve to baseline at the AM test and an 11 % improvement at the PM test. 
By comparison, subjects in the pl acebo group showed a 6% improvement at the AM test 
and a 4% improvement at the PM Test. The mean diffe rence between groups was not 
significant (P<.08). 
Divided Attention: The primary measure of divided attention was the secondary 
task reaction time and total score for the CCAB Mark Numbers Test. The Group x 
Sess ion effect was sign ificant for the secondary task reaction time (P =.038) and fo r the 
Total Score (P =.032) The secondary task reaction time decreased for NADH subjects by 
0.15 seconds and increased by 0.44 seconds for the pl acebo subjects (P =.0 16). T he PM 
Total score for NADH subjects increased by 77 .5 points, compared to an increase of 19.2 
points for placebo subjects (P = .01 1) [Fi gure 3 Here]. 
Visual Perceptual Speed and Accuracy: The CogScreen Matching to Sample and 
Visual Sequence Comparison tests provided measures of visual perceptual speed and 
accuracy. For the Visual Sequence Comparison Test there was a significant Group x 
Session interaction for the throughput measure (con·ect responses per minute; P = .05). 
NADH subjects correctly completed 5.4 more items per minute at the PM test compared 
to baseline. By comparison, the placebo subjects correctly completed 1.4 more items per 
minute (P = .026). There was no significant Group x Session effect for the Matching to 
Sample Test. Nevertheless, the NADH group showed a tendency (P =.078) for more 
improvement in throughput from baseline to PM testing; 4.9 more correct responses per 
minute compared to 1.0 more correct response per minute for placebo subjects [Figure 4 
Here]. 
Psychomotor Performance: The CogScreen Dual Task Test Tracking Alone 
measure provides a measure of skilled motor activity . This clitical instability tracking 
I L 
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test measures the number of tracking failures during a 90 second trial. There is generally 
an improvement (i.e., a practice effect) on this test reflected by fewer subjects making 
tracking eITors over trials. This pattem of performance is evident for the NADH group 
where 31 % had tracking failures at baseline, 33% at the AM test and 11 % at the PM test. 
In contrast , for the subjects in the placebo group, 29% had tracking failures at baseline, 
41 % at the AM test and 29% at the PM test. Group comparisons show a trend for better 
tracking performance for NADH subjects (P<.09). 
Sleepiness and Mood: At baseline, 14 subjects (82%) in the NADH group rated 
their sleepiness a 1 or 2 on the 7-point Stanford Sleepiness Scale (SSS) and three subjects 
rated their sleepiness a 3. Sixteen placebo subjects (94%) rated their sleepiness a 1 or 2 
at baseline. One placebo subject had a sleepiness rating of 3. One NADH subject was an 
extreme outlier on the SSS and was excluded from the SSS analyses. In the moming, 
both groups had identical sleepiness ratings; six in each group (35%) had a rating of 1 or 
2 and 11 (65 %) had ratings of 3 or more. However, in the afternoon there was a trend 
toward less sleepiness in the NADH group (p=.07); eight had ratings of 1 or 2 and nine 
had ratings of 3 or more. For the placebo group, four subjects had ratings of 1 or 2 and 
13 had ratings of 3 or more [Figure 5 Here]. There were no significant differences found 
between groups on measures of self-reported fatigue and activity level. 
DISCUSSION 
The study was designed to transport subjects across time zones, in a controlled 
environment, so that we could assess the impact of jet lag as well as the effects of a 
potential jet lag countermeasure. Results indicated that an overnight ("red-eye") flight 
across four time zones was effective in generating subjective symptoms of jet lag 
including fatigue and sleepiness. The cognitive test employed in the study (CogScreen) 
detected cognitive changes following the flight. Furthermore, stabilized NADH was 
12 
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found to have a beneficial effect on cognitive functioning and sleepiness when 
administered upon anival. NADH appears to mitigate the effects of jet lag on cognitive 
and psychomotor functions considered particularly sensitive to sedation; vigilance, 
working memory, visuomotor tracking and divided attention. In addition, NADH showed 
a trend to reduce the number of subjects experiencing self-reported sleepiness. 
Though there were 14 subjects that repol1ed headaches during the study, only 2 
occurred after the administration of NADH. Because only 2 occurred after the 
supplement, we deemed that there were no adverse effects attributable to it. The absence 
of problems corresponds to the findings in the administration of NADH in other clinical 
studies (20 , 22, 23). 
On measures of vigilance there was a notable increase in lapses of attention , as 
reflected by omission errors on the two continuous performance tests (KCPT and ANAM 
Running Memory Test). These lapses of attention were most evident in the moming 
following the flight. By the aftemoon, only 14% of NADH subjects had omission errors 
on the KCPT and mean accuracy on the Running Memory Test was 96%. In contrast, 
37% of placebo subjects made omission errors on the KCPT and the mean accuracy on 
the Running Memory Test was 91 %. 
NADH also appears to have a protective effect on working memory, the ability to 
temporarily hold information in mind and to perform a mental operation on the 
information. On the morning test, subjects who received NADH showed an improvement 
in accuracy on the Shifting Attention Test - Instruction Condition. In sharp contrast, 
accuracy dropped for subjects in the placebo condition. On a second measure of working 
memory, ANAM Math Test, there was also a trend for better performance. 
Jet lag clearly has a negatively impact on divided attention, the ability to perform 
simultaneous mental operations. During the moming test session, subjects who received 
placebo were 0.15 seconds slower, compared to baseline, in their response to the 
secondary task on the CCAB Mark Numbers Test. By comparison, subjects who 
13 
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received NADH improved, compared to baseline, by 0.44 seconds on this task. 
Furthermore, the total score on the Mark Numbers test improved significantly more for 
subjects who received NADH. 
On two measures of visual perceptual speed and accuracy (CogScreen Visual 
Sequence Compari son and Matching to Sample), NADH subjects demonstrated greater 
14 
improvement in the number of correct responses per minute at the afternoon test session, 
compared to the pl acebo subjects. 
The impact of the jet lag protoco l on sleepiness is evident in the ratings provided 
by subjects on the Stanford Sleepiness Scale. During the morning test session 57.1 % of 
the subjects in the NADH group and 62.5 % of the subjects in the placebo group reported 
an increase in sleepiness compared to baseline. By the afternoon test session, 57 .7% of 
the NADH subj ects were no longer reporting an increase in sleepiness relative to their 
baseline rating. By compalison , only 25 % of the placebo subjects were no longer 
reporting increased sleepiness. 
We have subsequently had an opportunity to test an additional 11 subjects 
fo llowing the same protocol. With the addition of these subjects (n=46), the effect on 
sleepiness, as measured by the Stanford Sleepiness Scale, reached significance (P<.02). 
At the afternoon test 48% of NADH subjects reported no sleepiness, compared to 18% of 
placebo subjects. 
The public health, occupational health, and economic impact of jet lag have likely 
been underestimated (28). There are an increasing number of business travelers making 
transcontinental and intercontinental flights. These travelers are subjected to the effects 
of jet lag demonstrated in the current study. The "jet lagged traveler" is more likely to 
experience lapses of attention (i.e., vigilance errors), to have difficulty concentrating (i.e., 
working memory difficulty), and to be less efficient at handling the demands of the work 
environment (i .e., decreased divided attention). In addition the jet lagged traveler feels 
less alert, less active and more fatigued. For the traveling athlete these effects of jet lag 
14 
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are likely to be ev ident in reduced performance. Travelers, and the aircrew who transpol1 
them, need to be made more aware of the effects and consequences of jet lag. They also 
need to learn about the benefits and lisks of different jet lag countermeasures(ll). 
Employers, business travelers, and athletes need to adjust their expectations and allow for 
an adequate opportunity to recover from the effects of jet lag. 
The implications of this work are that activities such as executive decision making 
or athletic performance that require attention to multiple tasks, continuous concentration 
and rapid interpretation of visual cues will be affected by travel across time zones. 
Stabilized NADH was effective in mitigating against these cognitive effects. Piloting an 
aircraft is critically dependent on vigilance, memory and visual perception . Solutions for 
jet lag that involve attempts to realign circadian rhythms appear to be especially 
impractical for commercial pilots (29). In contrast, NADH may prove to be especiall y 
useful as a jet lag or fatigue countermeasure for aircrew. 
Sublingual stabilized NADH appears to be a suitable short-term countermeasure 
for the effects of jet lag on cognition and sleepiness. In the current study, subjects 
receiving NADH showed less reduction of cognitive functioning and were more likely to 
be functioning at their baseline (pre-flight) level than subjects who received placebo. 
Further studies are needed to replicate and extend the present findings. In particular, 
there is a need to investigate optimal dosing parameters for this use of NADH. What is 
the duration of the effect of NADH on cognition and self-reported sleepiness? 
Furthermore, there is a dearth of evidence on the duration and course of the cognitive 
performance decrements over time that result from jet lag. Would NADH be helpful for 
symptoms occuning 48 to 72 hours after travel? Other conditions where s leep schedules 
and circadian rhythms are disturbed such as night call and shift work should also be 
investi gated. 
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Legends fo r Illustrations 
Figure 1: Mean accuracy by group on the ANAM Running Memory Test, across the 3 
test sessions. Results show a significant group by session interaction (P=.036). 
Note: Baseline refers to the testing in San Diego on the day of the flight; AM 
refers to morning testing in W ashington, DC; PM refers to aftern oon testing in 
Washington, DC. 
Figure 2: Mean accuracy by group on the Shifting Attention Test Instructi on Condition , 
across the 3 test sessions. Results show a signi ficant group by session effect 
(P<.05) . 
20 
Figure 3: Reaction time on the secondary task of the Complex Cogn iti ve Assessment 
Battery Mark Numbers Test, across the 3 test sessions. Results show a signi ficant 
group by session effect (P = .038) . 
Figure 4: Correct responses per minute (throughput) on the Visual Sequence Comparison 
test , across the 3 test sessions. Results show a significant group by session 
interaction (P = .05). 
Figure 5: Subjects reporting sleepiness on the Stanford Sleepiness Scale (rating> 2). 
Results show a trend for less sleepiness in the NADH group in the PM (P=.07). 
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